Forty years experience of treating cancer of unknown primary

References

• Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990–2005
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Pavlidis N. Cancer of unknown primary origin. Oncologist 1997; 2: 142–52
   PubMedGoogle Scholar
• Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005; 54: 243–50
   PubMed Web of Science ®Google Scholar
• Krementz ET, Cerise EJ, Foster DS, Morgan LR., Jr. Metastases of undetermined source. Curr Probl Cancer 1979; 4: 4–37
   PubMedGoogle Scholar
• Greco FA, Hainsworth JD. Cancer of unknown primary site. Cancer: Principles and practice of oncology4th ed, TV DeVita, S. Hellman, S.A. Rosenberg. J.B. Lippincott Co, Philadelphia 1997; 2423–43
   Google Scholar
• Silverberg E, Luber J. Cancer Statistics 1987; 37: 2–19
   Web of Science ®Google Scholar
• Visser O, Coebergh JWW, Schouten LJ. Incidence of cancer in the Netherlands. The Netherlands Cancer Registry, Utrecht 1993; 1993
   Google Scholar
• Frost P, Raber MN, Abbruzzese JL. Unknown primary tumors as a unique clinical and biologic entity: A hypothesis. Cancer Bull 1989; 41: 139–41
   Google Scholar
• Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094–103
   PubMed Web of Science ®Google Scholar
• Bell CW, Pathak S, Frost P. Unknown primary tumors: Establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. Cancer Res 1989; 49: 4311–5
   PubMedGoogle Scholar
• Abbruzzese JL, Lenzi R, Raber MN, Pathak S, Frost P. The biology of unknown primary tumors. Semin Oncol 1993; 20: 238–43
   PubMed Web of Science ®Google Scholar
• Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: Abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol 1985; 21: 185–9
   PubMedGoogle Scholar
• Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 1995; 15: 2563–7
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 2000; 18: 632–5
   PubMed Web of Science ®Google Scholar
• Fizazi, K, Voigt, JJ, Lesimple, T, Lortholary, A, Bugat, R, et al. Carcinoma of unknown primary (CUP): Are the tyrosine kinase HER-2, EGF-R, and c-Kit suitable targets for therapy?. Proc Am Soc Clin Oncol 2003;22:3549 ( abstr).
   Google Scholar
• Rashid, A, Hess, KR, Lenzi, R, Raber, MN, Abbruzzese, JL, Varadhachary, GR. Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP). Proc Am Soc Clin Oncol 2005;23:9683 ( abstr).
   Google Scholar
• Dova L, Georgiou I, Vartholomatos G, Kolaitis N, Malamou-Mitsi V, Pentheroudakis G, et al. EGFR and C-KIT/CD117 gene mutational screening and oncoprotein expression in patients with cancer of unknown primary: Implications for molecular pathophysiology and therapy. Eur J Cancer 2005; 3: 424 (abstr 1466)
   Google Scholar
• Van de Wouw AJ, Jansen RL, Griffioen AW, Hillen HF. Clinical and immunonohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004; 24: 297–301
   PubMedGoogle Scholar
• Bar-Eli M, Abbruzzese JL, Lee-Jackson D, Frost P. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 1993; 13: 1619–23
   PubMedGoogle Scholar
• Hillen HF, Hak LE, Joosten-Achjanie SR, Arends JW. Microvessel density in unknown primary tumors. Int J Cancer 1997; 74: 81–5
   PubMed Web of Science ®Google Scholar
• Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, et al. Angiogenesis in cancer of unknown primary: A clinicopathological study of CD34, VEGF and TSR-1. BMC Cancer 2005; 5: 25–32
   PubMedGoogle Scholar
• Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, et al. Matrix metalloproteinases in carcinoma of unknown primary. Cancer 2005; 104: 2282–7
   PubMed Web of Science ®Google Scholar
• Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: Development of a diagnostic algorithm. Clin Cancer Res 2005; 11: 3766–72
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RS. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995; 13: 274–82
   PubMedGoogle Scholar
• Atkin NB, Baker MC. Specific chromosome change, i(12p), in testicular tumours?. Lancet 1982; 2: 1349
   PubMed Web of Science ®Google Scholar
• Ilson DH, Motzer RJ, Rodriguez E, Chaganti RSK, Bosl GJ. Genetic analysis in the diagnosis of neoplasm of unknown primary tumor site. Semin Oncol 1993; 20: 229–37
   PubMedGoogle Scholar
• Karsell PR, Sheedy PF, O'Connell MJ. Computed tomography in search of cancer of unknown origin. JAMA 1982; 248: 340–3
   PubMed Web of Science ®Google Scholar
• McMillan JH, Levine E, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. Radiology 1982; 143: 143–6
   PubMedGoogle Scholar
• Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg 1990; 125: 210–4
   PubMedGoogle Scholar
• Orel SG, Weinstein SP, Schnall MD, Reynolds CA, Schuchter LM, Fraker DL, et al. Breast MR Imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 1999; 212: 543–9
   PubMed Web of Science ®Google Scholar
• Rades D, Kuhnel G, Wildfang I, Borner AR, Schmoll HJ, Knapp W. Localised disease in cancer of unknown primary (CUP): The value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001; 12: 1605–9
   PubMed Web of Science ®Google Scholar
• Casciato DA, Tabbarah HJ. Metastases on unknown origin. Cancer treatment3rd ed, C.M. Haskell. WB Saunders, Philadelphia 1990; 798–881
   Google Scholar
• Pavlidis N, Kalef-Ezra J, Briassoulis E, Skarlos D, Kosmidis P, Saferiadis K, et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 1994; 22: 162–7
   PubMedGoogle Scholar
• Shahangian S, Fritsche HA. Serum tumor markers as diagnostic aids in patients with unknown primary tumors. Cancer Bull 1989; 41: 152–6
   Google Scholar
• Abbruzzese JL, Raber MN, Frost P. The role of CA 125 in patients with unknown primary tumors. Proc Am Soc Clin Oncol 1991; 10: 39
   Google Scholar
• Johnson R, Castro R, Ansfield F. Response of primary unknown cancers to treatment with 5-fluorouracil (NSC-19893). Cancer Chemoth Reports 1964; 38: 63
   PubMedGoogle Scholar
• Moertel C, Reitemeier R, Schutt AJ, Hahn RG. Treatment of the patient with adenocarcinoma of unknown origin. Cancer 1972; 30: 1469–72
   PubMed Web of Science ®Google Scholar
• Valentine J, Rosenthal S, Arseneau J. Combination chemotherapy for adenocarcinoma of unknown primary origin. Cancer Clin Trials 1979; 2: 265–8
   Google Scholar
• McKeen E, Smith F, Haidak D. Fluorouracil, adriamycin and mitomycin-C for adenocarcinoma of unknown origin (abstr). Proc Am Assoc Cancer Res 1980; 21: 358
   Google Scholar
• Anderson H, Thatcher N, Rankin E, Wagstaff J, Scarffe JH, Crowther D. VAC (vincristine, adriamycin and cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. Eur J Cancer Clin Oncol 1983; 19: 49–52
   PubMedGoogle Scholar
• Fiore JJ, Kelsen DP, Gralla RJ, Casper ES, Magill G, Cheng E, et al. Adenocarcinoma of unknown primary origin: Treatment with vindesine and doxorubicin. Cancer Treat Rep 1985; 69: 591–4
   PubMedGoogle Scholar
• Goldberg RM, Smith FP, Ueno W, Ahlgren JD, Schein PS. Fluorouracil, adriamycin and mitomycin in the treatment if unknown primary. J Clin Oncol 1986; 4: 395–9
   PubMed Web of Science ®Google Scholar
• Alberts AS, Falkson G, Falkson HC, van der Merwe MP. Treatment and prognosis of metastatic carcinoma of unknown primary: Analysis of 100 patients. Med Pediatr Oncol 1989; 17: 188–92
   PubMedGoogle Scholar
• Al-Idrissi HY. Combined 5-fluorouracil, adriamycin and mitomycin-C in the management of adenocarcinoma metastasizing to the liver from an unknown primary site. J Int Med Res 1990; 18: 425–9
   PubMedGoogle Scholar
• Kambhu SA, Kelsen DP, Fiore J, Niedzwiecki D, Chapman D, Vinciguerra V, et al. Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. Am J Clin Oncol 1990; 13: 55–60
   PubMedGoogle Scholar
• Kelsen D, Martin DS, Colofiore J, Sawyer R, Coit D. A phase II trial of biochemical modulation using N-phosphonacetyl-L- aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. Cancer 1992; 70: 1988–92
   PubMedGoogle Scholar
• van der Gaast A, Henzen-Logmans SC, Planting AS, Stoter G, Verweij J. Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site. Ann Oncol 1993; 4: 789–90
   PubMedGoogle Scholar
• Jadeja, J, Legha, S, Burgess, M. Combination chemotherapy with 5-fluorouracil, adriamycin, cyclophosphamide, and cis-platinum in the treatment of adenocarcinoma of unknown primary and undifferentiated carcinomas. Proc Am Soc Clin Oncol 1983;926( abstr).
   Google Scholar
• Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: Recognition of a treatable syndrome. Ann Intern Med 1986; 142: 547–53
   Google Scholar
• Becouarn Y, Brunet R, Barbe-Gaston C. Fluorouracil, doxorubicin, cisplatin and altretanine in the treatment of metastatic carcinoma of unknown primary. Eur J Cancer Clin Oncol 1989; 25: 861–8
   PubMedGoogle Scholar
• van der Gaast, Verweij J, Henzen-Logmans SC, Rodenburg CJ, Stoter G. Carcinoma of unknown primary: Identification of a treatable subset?. Ann Oncol 1990; 1: 119–22
   PubMedGoogle Scholar
• Raber MN, Faintuch J, Abbruzzese LJ, Sumrall C, Frost P. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. Ann Oncol 1991; 2: 519–20
   PubMedGoogle Scholar
• Lenzi R, Abbruzzese J, Amato R. Cisplatin, 5-fluorouracil and follinic acid for the treatment of carcinoma of unknown primary: A phase II study. Proc Am Soc Clin Oncol 1991; 10: 301 (abstr)
   Google Scholar
• Gill I, Guaglianone P, Grunberg SM, Scholz M, Muggia FM. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary. Anticancer Res 1991; 11: 1231–5
   PubMedGoogle Scholar
• Hainsworth, JD, Johnson, DH, Greco, FA. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site. Cancer 1991;67(1 Suppl):310–4.
   PubMedGoogle Scholar
• Wagener DJ, de Mulder PH, Burghouts JT, Croles JJ. Phase II trial of cisplatin for adenocarcinoma of unknown primary site.IKZ/IKO Clinical Research Group. Eur J Cancer 1991; 27: 755–7
   PubMedGoogle Scholar
• Pavlidis N, Kosmidis P, Skarlos D, Briassoulis E, Beer M, Theoharis D, et al. Subsets of tumors responsive to cisplatin or carcboplatin combinations in patients with carcinoma of unknown primary site. Ann Oncol 1992; 3: 631–4
   PubMedGoogle Scholar
• Khansur T, Allred C, Little D, Anand V. Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. Cancer Invest 1995; 13: 263–6
   PubMed Web of Science ®Google Scholar
• Farrugia DC, Norman AR, Nicolson MC, Gore M, Bolodeoku EO, Webb A, et al. Unknown primary carcinoma: Randomized studies are needed to identify optimal treatments and their benefits. Eur J Cancer 1996; 32A: 2256–61
   PubMedGoogle Scholar
• Rigg A, Cunningham D, Gore M, Hill M, O'Brien M, Nicolson M, et al. A phase I/II study of leucovorin, carboplatin, and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Br J Cancer 1997; 75: 101–5
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Tsavaris N, Fountzilas G, Athanasiadis A, Kosmidis P, Bafaloukos D, et al. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-operative Oncology Group Phase II study. Oncology 1998; 55: 426–30
   PubMedGoogle Scholar
• Falkson CI, Cohen GL. Mitomycin, epirubicin and cisplatin versus mitomycin-C alone as therapy for carcinoma of unknown primary origin. Oncology 1998; 55: 116–21
   PubMed Web of Science ®Google Scholar
• Lofts FJ, Gogas H, Mansi JL. Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFT arm). Ann Oncol 1999; 10: 1389–92
   PubMedGoogle Scholar
• Warner E, Goel R, Chang J, Chow W, Verma S, Dancey J, et al. A multicenter phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Br J Cancer 1998; 77: 2376–80
   PubMedGoogle Scholar
• Parnis FX, Olver IN, Kotasek D, Norman J, Taylor A, Russell J, et al. Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site. Ann Oncol 2000; 11: 883–4
   PubMedGoogle Scholar
• Voog E, Merrouche Y, Trillet-Lenoir V, Lasset C, Peaud PY, Rebattu P, et al. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am J Clin Oncol 2000; 23: 614–6
   PubMedGoogle Scholar
• Guardiola E, Pivot X, Tchicknavorian X, Magne N, Otto J, Thyss A, et al. Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: A phase II trial. Am J Clin Oncol 2001; 24: 372–5
   PubMedGoogle Scholar
• Karapetis CS, Yip D, Virik K, Strickland A, Ryder K, Cowling M, et al. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site. Med Oncol 2001; 18: 23–32
   PubMedGoogle Scholar
• Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pinguet F. Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematolopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 2002; 94: 840–6
   PubMedGoogle Scholar
• Macdonald AG, Nicolson MC, Samuel LM, Hutcheon AW, Ahmed FY. A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (UCF) in the treatment of patients with carcinoma of unknown primary site. Br J Cancer 2002; 86: 1238–42
   PubMedGoogle Scholar
• Balana C, Manzano JL, Moreno I, Cirauqui B, Abad A, Font A, et al. A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol 2003; 14: 1425–9
   PubMed Web of Science ®Google Scholar
• Piga A, Gesuita R, Catalano V, Nortilli R, Getto G, Cardillo F, et al. Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination. Oncology 2005; 69: 135–44
   PubMedGoogle Scholar
• Pittman KB, Olver IN, Koczwara B, Kotasek D, Patterson WK, Keefe DM, et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: A phase 2 Adelaide Cancer Trials and Education Collaborative Study. Br J Cancer 2006; 95: 1309–13
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997; 15: 2385–93
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II study. The Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18: 3101–17
   PubMed Web of Science ®Google Scholar
• Greco FA, Burris HA 3rd, Erland EB, Gray JR, Kalman LA, Schreeder MT, et al. Carcinoma of unknown primary site. Cancer 2000; 89: 2655–60
   PubMed Web of Science ®Google Scholar
• Bouleuc C, Saghatchian M, Di Tullio L, Louvet Ch, Levy E, Di Palma M, et al. A multicenter phase II study of docetaxel and cisplatin in the treatment of cancer of unknown primary site. Proc Am Soc Clin Oncol 2001; 137b: 2298
   Google Scholar
• Darby AJ, Richardson L, Nokes L, Harvey M, Hassan A, Iveson T. Phase II study of single agent docetaxel in carcinoma of unknown primary site. Proc Am Soc Clin Oncol 2001; 100b: 2151
   Google Scholar
• Gothelf A, Daugaard G, Nelausen K. Paclitaxel, cisplatin and gemcitabine in the treatment of unknown primary tumours, a phase II study. Proc ESMO 2002; 25: 88
   Google Scholar
• Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richard SP, et al. Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20: 1651–6
   PubMed Web of Science ®Google Scholar
• Greco FA, Rodriquez GI, Shaffer DW, Hermann R, Litchy S, Yardley DA, et al. Carcinoma of unknown primary site: Sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: A Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004; 9: 644–52
   PubMed Web of Science ®Google Scholar
• Park YH, Ryoo BY, Choi SJ, Yang SH, Kim HT. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 2004; 34: 681–5
   PubMed Web of Science ®Google Scholar
• Pouessel D, Culine S, Becht C, Ychou M, Romieu G, Fabbro M, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004; 100: 1257–61
   PubMed Web of Science ®Google Scholar
• El-Rayes BF, Shields AF, Zalupski M, Heilbrum K, Jain V, Terry D, et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol 2005; 28: 152–6
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006; 24: 3548–54
   PubMed Web of Science ®Google Scholar
• Woods RL, Fox RM, Tattersall MH, Levi JA, Brodie GN. Metastatic adenocarcinomas of unknown primary site: A randomized study of two combination-chemotherapy regimens. N Engl J Med 1980; 303: 87–9
   PubMed Web of Science ®Google Scholar
• Shild RA, Kennedy PS, Chen TT, Athens JW, O'Bryan RM, Balcerzak SP. Management of patients with metastatic adenocarcinoma of unknown origin: A Southwest Oncology Group Study. Cancer Treat Rep 1983; 67: 77–9
   PubMedGoogle Scholar
• Milliken ST, Tattershall MH, Woods RL, Coates AS, Levi JA, Fox RM, et al. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987; 23: 1645–8
   PubMedGoogle Scholar
• Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ. Lack of value for cisplatin added to mitomycin / doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 1987; 10(1)82–5
   PubMedGoogle Scholar
• Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Rujol H. Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy. Ann Oncol 1999; 10: 569–75
   PubMedGoogle Scholar
• Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, et al. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000; 11: 211–5
   PubMed Web of Science ®Google Scholar
• Dowell J, Garrett AM, Shyr Y, Johnson DH, Hande KR. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001; 91: 592–7
   PubMed Web of Science ®Google Scholar
• Lortholary A, Culine S, Bouzy J. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary: Results of a randomized phase II study. Proc Am Soc Clin Oncol 2002; 153a: 609
   Google Scholar
• Assersohn L, Norman AR, Cunningham D, Iveson T, Seymour M, Hickish T, et al. A randomized study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. Eur J Cancer 2003; 39: 1121–8
   PubMedGoogle Scholar
• Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21: 3479–82
   PubMed Web of Science ®Google Scholar
• Huebner G, Steinbach S, Kohne CH, Stahl M, Kretzschmar A, Eimermacher A, et al. Paclitaxel (P)/Carboplatin (C) versus gemcitabine (G)/vinorelbine (V) in patients with adeno-or undifferentiated carcinoma of unknown primary (CUP) – A randomized prospective phase -II- trial. Proc Am Soc Clin Oncol 2005; 23: 330s, (Abstr 4089)
   Google Scholar
• Hainsworth JD, Burris HA 3rd, Calvert SW, Willcutt NT, Scullin DC, Jr, Bramham J, et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2001; 19: 335–9
   PubMed Web of Science ®Google Scholar
• Culine S, Ychou M, Fabbro M, Romieu G, Cupissol D. 5-Fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res 2001; 21: 1455–7
   PubMed Web of Science ®Google Scholar
• Pouessel D, Culine S, Becht C, Romieu G, Fabbro M, Ychou M, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 2003; 23(3C)2801–4
   PubMedGoogle Scholar
• Hainsworth JD, Spigel DR, Raefsky EL, Kuzur ME, Yost K, Kommor M, et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: A Minnie Pearl Cancer Research Network Phase II trial. Cancer 2005; 104: 1992–7
   PubMed Web of Science ®Google Scholar
• Frank RC, Kaplan F, Nair S. Response of carcinoma of unknown primary site affecting bone to thalidomide. Lancet Oncol 2005; 6: 534–5
   PubMedGoogle Scholar
• Asakura H, Takashima H, Mitani M, Habe R, Seo R, Yokoe K, et al. Unknown primary carcinoma, diagnosed as inflammatory breast cancer, and successfully treated with trastuzumab and vinorelbine. Int J Clin Oncol 2005; 10: 285–8
   PubMedGoogle Scholar
• Hainsworth JD, Spigel DR, Thompson DS, Shipley DL, Zubkus JD, Toomey MA, et al. Bevacizumab plus erlotinib in patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol 2006; 24: 129s, [Abstract3033]
   PubMedGoogle Scholar
• Chen KT, Flam MS. Peritoneal papillary serous carcinoma with long-term survival. Cancer 1986; 58: 1371–3
   PubMedGoogle Scholar
• Ransom DT, Patel SR, Keeney GL, Malkasian GD, Edmonson JH. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer 1990; 66: 1091–4
   PubMed Web of Science ®Google Scholar
• van der Gaast A, Verweij J, Henzen-Logmans SC, Rodenburg CJ, Stoter G. Carcinoma of unknown primary: Identification of a treatable subset. Ann Oncol 1990; 1: 119–22
   PubMedGoogle Scholar
• Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988; 109: 364–71
   PubMed Web of Science ®Google Scholar
• Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227–32
   PubMed Web of Science ®Google Scholar
• Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, McNeese M. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 1990; 66: 1461–7
   PubMed Web of Science ®Google Scholar
• Jackson B, Scott-Conner C, Moulder J. Axillary metastasis from occult breast carcinoma: Diagnosis and management. Am Surg 1995; 61: 431–4
   PubMedGoogle Scholar
• Vlastos G, Jean ME, Mirza AN, Mizza NQ, Kuerer HM, Ames FC, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 2001; 8: 425–31
   PubMedGoogle Scholar
• Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000; 55: 121–9
   PubMed Web of Science ®Google Scholar
• Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: Cut down a tree to get an apple?. Int J Radiat Oncol Biol Phys 2001; 50: 727–33
   PubMed Web of Science ®Google Scholar
• Ayoub JP, Hesds KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumours metastatic to liver. J Clin Oncol 1998; 16: 2105–12
   PubMedGoogle Scholar
• Hogan BA, Thornton FJ, Brannigan M, Browne TJ, Pender S, O’ Kelly P, et al. Hepatic metastases from an unknown primary neoplasm (UPN): Survival, prognostic indicators and value of extensive investigations. Clin Radiol 2002; 57: 1073–7
   PubMed Web of Science ®Google Scholar
• Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M. Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol 2005; 29: 1224–32
   PubMedGoogle Scholar
• van der Gaast A, Verweij V, Planting AST, Hope WCJ, Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995; 13: 1720–5
   PubMedGoogle Scholar
• Abbzuzzese J, Abbruzzese MC, Hess Kr, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12: 1272–80
   PubMedGoogle Scholar
• Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20: 4679–83
   PubMed Web of Science ®Google Scholar
• Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR. The influence of comorbidities, age and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer 2006; 106: 2058–66
   PubMed Web of Science ®Google Scholar
• Seve P, Ray-Coquard I, Trillet-Lenoir V, Sawyer M, Hanson J, Broussolle C, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 2006; 107: 2698–705
   PubMed Web of Science ®Google Scholar